We are live on
!
Find out more
BFO
Boston Family Office Portfolio holdings
AUM
$1.5B
1-Year Est. Return
11.68%
This Fund
S&P 500
This Quarter
Est. Return
-0.22%
1 Year Est. Return
+11.68%
3 Year Est. Return
+44.44%
5 Year Est. Return
+55.04%
10 Year Est. Return
+251.5%
AUM
$777M
AUM Growth
-$10.7M
(-1.4%)
Cap. Flow
-$2.88M
Cap. Flow
% of AUM
-0.37%
Top 10 Holdings %
Top 10 Hldgs %
22.01%
Holding
267
New
2
Increased
69
Reduced
89
Closed
10
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Verizon
VZ
|
+$1.46M |
| 2 |
AGN
Allergan plc
AGN
|
+$662K |
| 3 |
Walt Disney
DIS
|
+$472K |
| 4 |
Weyerhaeuser
WY
|
+$319K |
| 5 |
ATW
Atwood Oceanics
ATW
|
+$311K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
VIVO
Meridian Bioscience Inc
VIVO
|
+$2.13M |
| 2 |
FRX
FOREST LABORATORIES INC
FRX
|
+$880K |
| 3 |
AbbVie
ABBV
|
+$539K |
| 4 |
NLSN
Nielsen Holdings plc
NLSN
|
+$388K |
| 5 |
State Street SPDR S&P China ETF
GXC
|
+$361K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 17.96% |
| 2 | Industrials | 14.1% |
| 3 | Technology | 12.24% |
| 4 | Consumer Staples | 9.88% |
| 5 | Energy | 8.23% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
Vanguard FTSE Emerging Markets ETF
VWO
$117B
| $23.3M | 3% |
559,611
+1,380
| +0.2% | +$61.3K |
|
2
Gilead Sciences
GILD
$165B
| $21.7M | 2.79% |
203,663
-2,035
| -1% | -$199K |
|
3
Johnson & Johnson
JNJ
$640B
| $19.6M | 2.52% |
183,906
-391
| -0.2% | -$40.6K |
|
4
State Street SPDR S&P 500 ETF Trust
SPY
$771B
| $19.2M | 2.46% |
97,201
-910
| -0.9% | -$180K |
|
5
ExxonMobil
XOM
$650B
| $17.9M | 2.3% |
189,838
-1,071
| -0.6% | -$107K |
|
|
CELG
6
DELISTED
Celgene Corp
CELG
| $16.2M | 2.08% |
170,543
-1,947
| -1% | -$176K |
|
|
SRCL
7
DELISTED
Stericycle Inc
SRCL
| $15.1M | 1.94% |
129,138
-221
| -0.2% | -$26.1K |
|
8
Procter & Gamble
PG
$340B
| $13.1M | 1.69% |
156,383
-1,100
| -0.7% | -$90.1K |
|
|
ANSS
9
DELISTED
Ansys
ANSS
| $12.7M | 1.63% |
167,699
+1,454
| +0.9% | +$114K |
|
10
Apple
AAPL
$4.97T
| $12.4M | 1.59% |
490,960
-10,284
| -2% | -$252K |
|
11
State Street SPDR S&P MIDCAP 400 ETF Trust
MDY
$26.4B
| $12.3M | 1.58% |
49,343
+107
| +0.2% | +$27.5K |
|
12
SLB Ltd
SLB
$72.7B
| $12.2M | 1.57% |
119,758
-310
| -0.3% | -$33.8K |
|
13
Union Pacific
UNP
$174B
| $12.2M | 1.57% |
112,197
-312
| -0.3% | -$32.3K |
|
14
General Mills
GIS
$20.2B
| $11.5M | 1.49% |
228,841
-300
| -0.1% | -$15.7K |
|
15
Oracle
ORCL
$339B
| $10.5M | 1.35% |
273,896
-704
| -0.3% | -$28.5K |
|
16
Middleby
MIDD
$6.01B
| $10.3M | 1.33% |
116,985
+1,722
| +1% | +$143K |
|
17
iShares Core S&P Small-Cap ETF
IJR
$109B
| $10M | 1.29% |
192,360
+1,572
| +0.8% | +$85.5K |
|
18
Rockwell Automation
ROK
$51.1B
| $10M | 1.29% |
91,033
+589
| +0.7% | +$69.2K |
|
|
MRSH
19
Marsh
MRSH
$94.3B
| $9.72M | 1.25% |
185,764
-430
| -0.2% | -$22.4K |
|
20
Berkshire Hathaway Class B
BRK.B
$1.1T
| $9.63M | 1.24% |
69,696
+128
| +0.2% | +$17.1K |
|
21
American Tower
AMT
$83.5B
| $9.42M | 1.21% |
100,622
+1,152
| +1% | +$110K |
|
22
GE Aerospace
GE
$364B
| $8.98M | 1.16% |
73,177
+53
| +0.1% | +$6.6K |
|
23
AptarGroup
ATR
$8.69B
| $8.97M | 1.15% |
147,801
-322
| -0.2% | -$20.5K |
|
24
Golar LNG
GLNG
$4.82B
| $8.86M | 1.14% |
133,399
-542
| -0.4% | -$34.3K |
|
25
PepsiCo
PEP
$196B
| $8.65M | 1.11% |
92,881
-175
| -0.2% | -$16K |
|
Similar funds
CP
JFGLC
AAM
TP
SCM
FMI
NSGL
RCW
Boston Family Office's Q3 2014 Portfolio in Review
As of Q3 2014, Boston Family Office held 267 positions worth $777M, down 1.4% from $788M the previous quarter. Its ten largest holdings account for 22% of the portfolio.
Trading was light in Q3 2014: portfolio turnover was 4.5%. Boston Family Office opened 2 new positions and exited 10, leaving the 267-position portfolio largely intact.
By sector, the portfolio is most concentrated in Healthcare at 18% of assets, up from 17% a quarter earlier, followed by Industrials and Technology.
- Boston Family Office's largest Q3 2014 buy was Allergan plc: 2,957 shares worth $713K.
- Boston Family Office added most to Verizon in Q3 2014, an estimated $1.46M increase.
- Boston Family Office's biggest Q3 2014 reduction was AbbVie, cutting an estimated $539K.
- Boston Family Office fully exited Meridian Bioscience Inc in Q3 2014, selling an estimated $2.13M.
- Boston Family Office's ten largest holdings make up 22% of its $777M portfolio in Q3 2014.
- Boston Family Office opened 2 new positions and closed 10 in Q3 2014.
- Boston Family Office's portfolio value fell 1.4% quarter-over-quarter to $777M.
Based on Boston Family Office's 13F filing for Q3 2014, filed 31 Oct 2014.